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Abstract  
The high prevalence of asymptomatic JC polyomavirus (JCV) infection in the general population indicates coexistence 
with the human host and efficient immune control in healthy individuals. For unknown reasons kidney-resident 
archetypic JCV strains can turn into neurotropic JCV strains which in hereditary or acquired states of 
immunodeficiency cause opportunistic infection and cytolytic destruction of glial cells or granule cell neurons resulting 
in progressive multifocal demyelination in the central nervous system (CNS) or cerebellar atrophy, respectively. 
Immunomodulatory or -suppressive therapies with specific monoclonal antibodies including natalizumab, efalizumab 
and rituximab have increased the risk of progressive multifocal leukoencephalopathy (PML) among treated patients, 
highlighting that symptomatic JCV infection of the CNS is associated with disturbances of adaptive immunity affecting 
B cells, antibodies, CD4+ and/or CD8+ T cells. To date, no specific therapy to overcome PML is available and the only 
way to eliminate the virus from the CNS is to reconstitute global immune function. However, since the identification of 
JCV as the causative agent of PML 40 years ago, it is still not fully understood, which components of the immune 
system prevent the development of PML and which immune mechanisms are involved in eliminating the virus from the 
CNS. This review gives an update about adaptive JCV-specific immune responses. 
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Introduction 
JC polyoma virus (JCV) is a particularly instructive example to learn more about the interplay between viral and host 
immune factors. Archetypic JCV strains infect the majority of healthy humans, primarily persist in the kidney, urinary 
tract, but also hematopoietic progenitor cells and niches including B cells (Egli et al, 2009; Frohman et al, 2014; Major, 
2010). As long as the individual’s immune function remains intact, JCV infection will not cause disease. In contrast, in 
situations of compromised immune control, JCV variants with altered tropism for oligodendrocytes or granule cell 
neurons cause severe destruction in the white or gray matter leading to progressive multifocal leukoencephalopathy 
(PML), JCV encephalitis or granule cell neuronopathy (GCN), respectively (Gheuens et al, 2013). Opportunistic JCV 
infection of the central nervous system (CNS) occurs in the context of hereditary (e.g. idiopathic CD4 lymphopenia, 
hyper IgE syndrome) or acquired states of immunodeficiency (symptomatic human immunodeficiency virus (HIV) 
infection, cancer, chemotherapy, organ transplantation), but has also been associated recently with immunomodulatory 
or -suppressive treatments of autoimmune diseases (e.g. natalizumab, rituximab, efalizumab) (Gillespie et al, 1991; 
Kleinschmidt-DeMasters and Tyler, 2005; Major, 2010; Zonios et al, 2008).  
In contrast to urinary excreted archetypic JCV strains, PML-associated JCV genotypes and genotype variants present 
characteristic mutations of the major capsid protein VP1 and rearrangements of the non-coding control region (NCCR), 
which probably allow entry and propagation in the CNS as well as preferential tropism for glial cells or neurons (Dang 
et al, 2012; Gorelik et al, 2011; Major, 2010; Reid et al, 2011). Moreover, whereas archetype JCV is secreted in the 
urine of healthy donors and PML patients and most probably circulates in the general population, PML-associated JCV 
NCCR rearrangements and VP1 mutations are only found in blood and CSF of PML patients (Reid et al, 2011). Up to 
date it is not clear, whether PML-associated alterations of the JCV genome occur inside or outside of the CNS and 
which mechanisms contribute to their occurrence or selection (Gorelik et al, 2011; Marshall et al, 2014; Reid et al, 
2011).  
How JCV accesses the CNS is unclear, but probably involves a hematogenous rather than a neural route: JCV enters the 
body via the upper respiratory tract, infects cells in the tonsils followed by persistent infection of CD34+ progenitor 
cells in the bone marrow and other hematopoietic niches. Under conditions of immunocompromise or -modulation the 
virus mobilizes from the bone marrow to the peripheral blood via CD34+ progenitor cells, B cells and/or other 
peripheral blood leukocyte subsets (Brew et al, 2010; Frohman et al, 2014; Houff et al, 1988). Whether JCV is attached 
to peripheral blood leukocytes or whether these cells are infected and active viral replication or transcription occurs 
remains to be elucidated. Either the migration of JCV-carrying peripheral blood leukocytes through the blood-brain-
barrier or crossing the barrier by infecting endothelial cells and reaching the brain as free virions may lead to viral entry 
to CNS tissue (Chapagain and Nerurkar, 2010).  
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To date, there is no treatment to prevent symptomatic JCV infection of the CNS. Currently, the only strategy to 
overcome PML is to restore general immune competence and immune surveillance of the CNS (Du Pasquier and 
Koralnik, 2003; Major, 2010).  This in turn can lead to an immune reconstitution inflammatory syndrome (IRIS), which 
is usually induced after washout of natalizumab by plasmapheresis in multiple sclerosis (MS) patients or initiation of 
highly active antiretroviral therapy (HAART) in AIDS (Cinque et al, 2003; Tan et al, 2011; Tan et al, 2009). PML-IRIS 
is characterized by massive immune cell infiltration and prominent inflammation of the JCV-infected CNS tissue 
usually leading to acute neurological deterioration, but also effective elimination of JCV by killing infected cells (Aly et 
al, 2011; Gheuens et al, 2011; Tan et al, 2011). The occurrence of IRIS in the CNS can be dangerous since it may cause 
additional damage in the brain and even lead to death of the patient by tissue swelling if not at least temporarily 
attenuated by immunosuppression (Tan et al, 2009). However, a substantial proportion (20-47%) of natalizumab-
associated PML patients do not clear JCV DNA from cerebrospinal fluid (CSF) despite IRIS (Dahlhaus et al, 2013; 
Ryschkewitsch et al, 2010). The significance of JCV persistence in the CSF despite clinically stably disease course after 
IRIS is unclear. In the following sections we will summarize the current facts and concepts concerning immunology of 
PML and at the end we will provide the reader with important open questions in this field. 
 
Humoral immune responses during JCV infection 
Despite identification of JCV as the causative agent of PML in 1971 (Padgett et al, 1971), it is until now not fully 
understood, which component/s of the immune system prevent the occurrence of PML in the vast majority of JCV-
infected individuals. The immunocompromised conditions promoting PML are characterized by loss of immune cells 
and/or perturbed function of adaptive immunity at several levels usually affecting B cells/antibodies, CD4+ and CD8+ T 
cells (Beltrami and Gordon, 2014; Du Pasquier et al, 2004; Gillespie et al, 1991; Major, 2010; Stuve, 2008).  
Seropositivity for JCV VP1-specific antibodies is currently most widely used to diagnose JCV infection and utilized for 
risk stratification in the context of natalizumab treatment for MS patients. 54% of MS patients are JCV-seropositive, 
tested in a 2-step assay (Gorelik et al, 2010). However, JCV viremia was observed in patients that were seronegative for 
anti-JCV VP1 antibodies, indicating that testing JCV-specific antibodies might not be sufficient to stratify the risk for 
some natalizumab-treated MS patients (Major et al, 2013). Interestingly, serum JCV VP1-specific antibody levels are 
increased in patients at onset of natalizumab-associated PML compared to natalizumab-treated MS patients (Trampe et 
al, 2012; Warnke et al, 2013; Warnke et al, 2014). PML survivors in the context of AIDS show significant increases in 
JCV-specific T cells and IgG responses in the peripheral blood, which are positively correlated with peripheral CD4+ T 
cell counts (Khanna et al, 2009). PML patients show generally JCV-specific oligoclonal IgG bands in the CSF and 
elevated intrathecal JCV VP1-specific antibodies with further increase at onset of IRIS (Aly et al, 2011; Sindic et al, 
1997; Warnke et al, 2014; Weber et al, 1997). This goes in line with the observation that plasma cells are prominent 
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among the brain immune infiltrates in PML-IRIS (Aly et al, 2011; Metz et al, 2012). The occurrence of PML during 
immunomodulatory treatments which affect B cells indicates the importance of B cell functions for controlling JCV. 
Rituximab depletes CD20+ B cells and thus leads to profound perturbation of the B cell homeostasis (Carson et al, 
2009; Major, 2010). It is currently unknown, if the depletion of B cells by rituximab results in PML because of reduced 
antibody responses against JCV, due to inefficient clearance of latently JCV-infected B cell subsets or perturbation of 
other functions of B cells such as antigen presentation to T cells (Cooper and Arnold, 2010). Natalizumab reduces not 
only the migration of CD19+ B cells and CD138+ plasma cells through the blood-brain-barrier (Stuve et al, 2006b), but 
also perturbs B cell homing by increasing the number of memory- and marginal zone-like B cells in the peripheral 
blood (Planas et al, 2012). The latter conditions and the fact that natalizumab induces the migration of CD34+ 
progenitor cells to the peripheral blood may influence the shaping and reactivation of neurotropic JCV variants 
(Frohman et al, 2014; Marshall et al, 2014).  
Antibodies are likely involved in neutralizing free JCV virions, preventing spread of free virus, but their role for 
immune control during persistent JCV infection and PML is still unknown. Interestingly, a recent proof-of-concept 
study demonstrated that 29% of sera from MS patients lack anti-JCV neutralizing activity despite the presence of anti-
JCV VP1 antibodies (Diotti et al, 2014). The fact that PML patients often show strong antibody responses within the 
serum and the CNS compartment at onset of PML and during the course of PML (Warnke et al, 2014; Weber et al, 
1997) questions the role of JCV-specific antibodies in the prevention of PML development and clearance of 
symptomatic JCV infection from brain. Interestingly, JCV variants with mutations in VP1 are often found in addition to 
prototype Mad-1 sequences in the CNS of PML patients (Gorelik et al, 2011; Reid et al, 2011). However, it is not 
known until now, whether mutations found in the VP1 capsid protein are driven by immune escape in order to avoid 
recognition by JCV-specific antibodies or whether JCV-specific antibodies are less effective because of  intracellular 
persistence of JCV without proper exposition of JCV-encoded proteins at the cell membrane for direct antibody 
recognition. Further investigations are needed to address the role of JCV-specific antibodies with respect to recognition 
and neutralization capacity. 
 
Cellular immune responses during JCV infection 
Role of CD8+ T cells in PML  
Diseases that are associated with risk for PML development and PML progression are often characterized by an 
attenuated T cell immune surveillance with loss of JCV-specific T cells (Koralnik et al, 2001). MS patients under 
natalizumab show in contrast to immunodeficiency disorders overall normal peripheral JCV-specific T cell responses, 
but natalizumab-associated inhibition of T cell entry into the brain, and hence compromise of immunosurveillance of 
the CNS is considered a pivotal factor for PML (Chalkias et al, 2014; Jilek et al, 2010). Numerous studies have 
-5-  
evaluated JCV-specific T cell responses with respect to antigen specificity, effector function and T cell subpopulations. 
Initial analysis of peripheral and CSF immune responses in PML survivors pointed to the importance of JCV VP1-
specific CD8+ T cells for better prognosis of PML (Du Pasquier et al, 2005; Du Pasquier et al, 2004; Gheuens et al, 
2011). JCV-specific CD8+ T cells appear ideally suited for elimination of JCV in PML, since their ”recognition 
structures”, i.e. HLA-class I molecules are expressed on neurons, oligodendrocytes and astrocytes. Characterization of 
brain samples from PML patients demonstrated brain infiltrates particularly consistent of CD8+ T cells (Wuthrich et al, 
2006). The proximity of CD8+ T cell infiltrates to JCV-infected glial cells indicated the recognition of the infected 
target cells. Another cross-sectional study of brain samples from HIV-patients who developed PML-IRIS proved the 
enrichment of cytotoxic CD8+ T cell infiltrates in the brain and their co-localization with JCV-infected oligodendrocytes 
in the context of IRIS (Martin-Blondel et al, 2013). Both studies included either HIV+ donors and/or donors with 
lymphopenic and immunosuppressed conditions having as hallmark a global reduced number of CD4+ T cells. In 
addition, a recent survey of five brain biopsies from natalizumab-associated PML-IRIS patients revealed in four out of 
five cases brain infiltrates dominated by CD8+ T cells which appeared to be present in adjacent white and gray matter 
(Metz et al, 2012). In fact this might vary between patients or over time, since an in depth analysis of a brain biopsy 
from a PML-IRIS patient revealed abundant infiltration of JCV VP1-specific CD4+ T cells besides brain-infiltrating 
JCV VP1-specific CD8+ T cells (Aly et al, 2011; Yousef et al, 2012).  
In the case of JCV GCN, which is characterized by productive infection of cerebellar granule cell neurons, one would 
expect a crucial role of CD8+ T cells in clearing JCV-infected neurons since these cells lack HLA class II expression 
(Dang and Koralnik, 2013). Indeed, a first case of natalizumab-associated JCV GCN with IRIS demonstrated abundant 
infiltration of CD8+ T cells (Schippling et al, 2013). At the current stage, existing data indicate that CD8+ JCV-specific 
T cells are required as effector cells to eliminate JCV from the brain. 
 
Role of CD4+ T cells in PML  
There is increasing evidence that CD4+ T cell immunity is also pivotal for controlling JCV infection. This is supported 
by the frequent occurrence of PML in the context of compromised CD4+ T cell immune surveillance, most notably 
AIDS, but also malignancies, transplant therapy and idiopathic CD4+ lymphopenia (Gillespie et al, 1991; Zonios et al, 
2008). Recovery of CD4+ T cell responses leads to elimination of JCV from the CNS of AIDS patients (Gasnault et al, 
2003). Generally, AIDS-associated PML-survivors reveal significant increases in JCV-specific CD4+ T cells as well as 
IgG responses (Khanna et al, 2009). Reduced CSF CD4+/CD8+ T cell ratio during natalizumab treatment indicates that 
entry of CD4+ T cells to the CNS is blocked much more efficiently than that of CD8+ T cells (Planas et al, 2012; Stuve 
et al, 2006a). Albeit often at lower numbers than CD8+ T cells, CD4+ T cells are also present or even found at higher 
numbers in CNS infiltrates during natalizumab-associated PML-IRIS (Aly et al, 2011). Moreover, widespread 
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expression of HLA class II was observed in JCV-infected brain tissue during natalizumab-associated PML-IRIS, 
supporting the notion that brain-infiltrating CD4+ T cells are essential in clearing JCV (Aly et al, 2011).  
Recent studies demonstrated strong associations of certain HLA class II alleles with JCV-specific immune responses. 
Thereby, heterozygotic HLA-DRB1*04:01+ donors revealed very low or even absent peripheral T cell responses to 
JCV, but potent JCV-specific antibody responses, proving a dominant-negative effect of this allele on JCV-specific T 
cell responses (Jelcic et al, 2013). Alleles within the HLA-DR1*15 haplotype are associated negatively, whereas the 
HLA-DQB1*06:03 haplotype is associated positively with JCV sero-status, evaluated by JCV-specific antibody 
response (Sundqvist et al, 2014). These data may indicate either a protective effect of HLA-DR1*15 haplotype on JCV 
infection or an effective immune control of JCV by CD4+ T cells in HLA-DR1*15-positive donors which does not 
require production of JCV-specific antibodies. A less effective JCV-specific CD4+ T cell control with higher viral 
turnover may result in a chronically higher stimulation of the JCV-specific B cells and increased production of JCV-
specific antibodies. 
The in depth analysis of brain infiltrates from a natalizumab-associated PML-IRIS patient revealed abundant and 
clonally expanded CD4+ T cells specific for JCV VP1 epitopes and HLA class II molecules of the HLA-DR1*15 
haplotype (Aly et al, 2011; Yousef et al, 2012). Further characterization of these brain-infiltrating VP1-specific T cell 
clones (TCC) demonstrated recognition of individual JCV VP1 peptides in the context of multiple HLA-DR and -DQ 
molecules, a phenomenon termed HLA cross-restriction (Figure 1) (Yousef et al, 2012). This ability to use multiple 
restriction elements to recognize the same and/or different peptides could ensure a more efficient activation since it 
enhances binding avidity and allows still activation in the case of limited expression of one restriction element (specific 
HLA molecule) in the tissue. An additional strategy of brain-infiltrating CD4+ T cells included a TCR bias for the 
immunodominant VP134-48 peptide of five different TCCs with almost identical TCR α- and β-chains but different 
sequences in the CDR3 regions and associated J-chains (Figure 1) (Yousef et al, 2012). The described TCR bias in 
brain-infiltrating JCV-specific CD4+ T cells explains the ability of different CD4+ T cell clonotypes to recognize the 
same viral epitope on a specific HLA molecule. This can be the result of continued antigenic stimulation, which leads to 
the selection of distinct T cell clonotypes with optimal TCR binding to an immunodominant viral epitope. TCR bias is a 
phenomenon which is also seen in the case of other persistent viral infections (Turner et al, 2006). Moreover, we 
observed brain-infiltrating CD4+ TCC with an unusual Th1-2 phenotype, secreting both interferon-γ (IFN-γ) and 
interleukin-4 (IL-4) as well as expressing both lineage transcription factors GATA-3 and T-bet. The secretion of IFN-γ 
induces the expression of HLA class I and II in the tissue, thereby enhancing antigen presentation of viral peptides 
whereas IL-4 is essential for promoting proliferation and differentiation of activated B cells, which explains the 
increasing intrathecal anti-JCV antibody production (Figure 1) (Aly et al, 2011; Yousef et al, 2012). Hence, the 
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simultaneous release of both cytokines allows a more effective support of both arms of the adaptive immune system, the 
T cell and antibody mediated  responses. Altogether, the various strategies used by brain-infiltrating JCV-specific CD4+ 
T cells support their importance in mounting an efficient JCV-specific immune response (Yousef et al, 2012). Long-
term resolution of PML is therefore probably not possible unless there is an efficient JCV-specific CD4+ T cell 
response.   
Interestingly, several studies associated the risk of PML with reduced T cell responses not only with respect to certain 
HLA alleles but also to loss of effector function. Reduced expression of CD62L on CD4+ T cells in HIV- and 
natalizumab-associated PML might not only provide a novel biomarker for PML but points to an altered activation 
status of peripheral T cells before onset of PML (Schneider-Hohendorf et al, 2014; Schwab et al, 2013). Another study 
reported either no detectable JCV-specific T cell response or an aberrant JCV-specific T cell response dominated by 
production of anti-inflammatory IL-10, as well as higher levels of IL-10 in the CSF in MS patients with natalizumab-
associated PML as opposed to MS patients without PML (Perkins et al, 2012). In HIV-associated PML patients, a 
higher frequency of PD-1-expressing JCV-specific CD8+ T cells was observed, indicating an increased exhaustion and 
subsequent loss of JCV-specific immune responses, which might lead to PML (Tan et al, 2012). However, these studies 
focused mainly on peripheral T cell responses, which probably differ from the functional phenotype and antigen 
specificity of JCV-specific T cells at the site of infection in the CNS.  
 
Antigen specificity  
JCV VP1 derived from the prototypical JC viral strain Mad-1 is currently used most commonly to asses JCV-specific 
antibody reactivity in serum and CSF in healthy donors, MS patients and PML patients (Gorelik et al, 2010; Sundqvist 
et al, 2014; Trampe et al, 2012; Warnke et al, 2013; Warnke et al, 2014). Since VP1 is the major capsid protein, it is 
considered the main target of antibody responses. Whether minor fractions of the general anti-JCV antibody response 
target other JC viral proteins, e.g. VP2 and/or VP3, remains to be determined. Furthermore, the distribution of 
immunodominant epitopes among VP1 and the importance of VP1 mutations found in PML-associated JCV strains 
(Gorelik et al, 2011) with respect to immune evasion of the antibody response remain to be determined.   
First attempts to characterize immunodominant CD8+ T cell epitopes were undertaken by in silico prediction of the best 
binders of 9-mer peptides to the most common HLA class I allele HLA-A*02:01 and subsequent in vitro verification 
using 51Cr-release assays and HLA-A*02:01/JCV peptide tetramer technology (Koralnik et al, 2002).  Thereby, 71% of 
HLA-A*02:01+ PML survivors were shown to elicit JCV-VP1100-108-specific cytotoxic CD8+ T cell response, in contrast 
to none of PML progressors (Koralnik et al, 2002). Another immunodominant CD8+ T cell epitope in the context of 
HLA-A*02:01, JCV-VP136-44, was identified by epitope mapping using overlapping 18- to 20-mer peptides spanning 
the JCV VP1 sequence and functional CD8+ T cell lysis experiments (Du Pasquier et al, 2003). HLA class I tetramer 
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staining showed, that 91% of HLA-A*02:01+ PML survivors elicit JCV-VP136-44-specific CD8+ T cells, and only 9% of 
PML progressors (Du Pasquier et al, 2003). We used overlapping 13- to 16-mer peptides spanning all JCV-encoded 
open reading frames, i.e. agnoprotein, VP1, VP2, VP3, large T antigen, small t antigen and T’ antigens T’135, T’136, 
and T’165, and thymidine incorporation to assess T cell proliferation and to identify immunodominant epitopes within 
the complete JCV proteome in a cohort of 49 healthy donors (Jelcic et al, 2013). In our study, the VP1100–109 peptide 
was represented by peptides VP191–105 and VP1101–115 in peptide pool 6, and the VP136–44 peptide was covered by peptide 
VP134–48 in pool 4, with each pool containin  5 differen            
immunodominant peptide pools. Furthermore, HLA-A*02:01-restricted JCV VP1100-108- and VP136-44-specific CD8+ T 
cells were also detected in a brain infiltrate of a patient during PML-IRIS patient by tetramer technology (Aly et al, 
2011). Interestingly, CD4+ T cells from the same brain infiltrate specimen recognized preferentially VP134–48 in the 
context of HLA-DQw6 among seven other immunodominant JCV epitopes, showing that CD8+ T cells and CD4+ T 
cells recognize related epitopes, and underscoring the relevance of JCV VP134–48 epitope (Aly et al, 2011; Yousef et al, 
2012). Broad reactivity of CD4+ and CD8+ T cells against each of the JCV proteins was recognized in MS patients and 
healthy donors by using intracellular cytokine staining and flow cytometry after stimulation with 5 peptide pools, which 
contained overlapping 15-mer peptides with each peptide pool covering one of the viral proteins, i.e. agnoprotein, VP1, 
VP2, large T antigen and small t antigen (Perkins et al, 2012). In this study, different viral proteins were 
immunodominant in different donors and most donors showed reactivity of both CD4+ and CD8+ T cells. However, 
systematic mapping data for single epitopes other than HLA-A*02:01-restricted JCV VP1100-108 and VP136-44 is still 
pending. 
By using thymidine incorporation assay in our epitope mapping study, proliferation and activation of CD4+ T cells was 
favoured over CD8+ T cells as shown by carboxyfluorescein succinimidyl ester (CFSE) dilution assay. With this 
approach multiple immunodominant epitopes in JCV VP1 and large T antigen have been mapped in the context of 
multiple HLA-class II alleles (Jelcic et al, 2013). Interestingly, JCV-specific T cell responses may be directed not only 
against JCV VP1 and large T antigen but also against all other JCV-encoded proteins. This epitope mapping study 
indicates a high intra- and interindividual variability in epitope specificity and immunodominant JCV CD4+ T cell 
epitopes. The analysis of brain-infiltrating T cells in a patient with PML-IRIS revealed not only that CD4+ T cells 
dominated over CD8+ T cells, and that CD4+ T cells recognized predominantly VP1 epitopes and to a lesser extent large 
T antigen epitopes, but also that JCV VP1-specific reactivity in the brain infiltrate specimen was considerably higher 
than in the CSF or peripheral blood (Aly et al, 2011). This indicates that analysis of JCV-specific immunity in the 
peripheral blood or CSF may not be representative for the immunological reaction at the site of CNS infection. Detailed 
studies of intracerebral immune responses in the context of JCV-infected neurons have not been conducted yet. 
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Lessons from immunological studies in PML 
PML is a serious adverse event that often leaves permanent neurological deficits and threatens the use of several highly 
efficient monoclonal antibodies such as natalizumab for MS treatment. In natalizumab-treated patients, risk 
stratification according to JCV-seropositivity, duration of treatment and prior long-term immunosuppressive therapies 
help to identify patients at higher risk for PML development in order to terminate treatment (Gorelik et al, 2010). Yet, 
we currently do not have a similarly efficacious and well-tolerated drug available for the treatment of MS patients with 
active disease after suspension of natalizumab treatment. Therefore, it would be highly desirable to establish 
prophylactic and/or therapeutic vaccination regimens.   
Currently, there are no specific treatments for PML except of reconstituting immunocompentence in the brain. Until 
now it is not fully understood, which components of the immune system are involved in prevention or resolution of JCV 
infection in the brain. Open questions concerning PML immunology and JCV-specific immunity are summarized in 
Table 1.  
Several studies have highlighted the importance of CD4+ and CD8+ T cells and B cells in JCV-specific immunity. TCR 
bias, avidity-enhancing HLA-cross-restriction and flexibility in T helper cell phenotype of brain-infiltrating cells as 
well as the large intra- and interindividual variability in epitope specificity and epitope immunodominance of peripheral 
JCV-specific T cells indicate that a variety of mechanisms is involved in keeping latent/persistent JCV infection in 
check. While it is not possible to tell at present, which cell population is most relevant, CD4+ JCV-specific T cells 
probably play a major role, but the other arms of adaptive immunity are also involved. JCV VP1 may represent the best 
candidate for stimulating JCV-specific CD4+ T cell responses, and the addition of an adjuvant would additionally boost 
the response. However, these conclusions are based on few studies with a limited number of cases. Most of the studies 
with higher case numbers investigated JCV-specific immunity in the peripheral blood, and not in the CSF or brain 
tissue. Big caveats are immune-escaping mechanisms of JCV and counter-mechanisms of JCV-specific immunity, as 
well as the role of genetic factors predisposing for PML and the interplay of CD4+ T cells, CD8+ T cells and B cells to 
control latent and symptomatic JCV infection. Before vaccination of generally immunocompromised-/deficient patients 
some degree of immunocompetence would have to be restored. Strategies to achieve prophylactic and/or therapeutic 
vaccination should actively be explored, since treatments for PML are urgently needed and boosting natural immunity 
against JCV appears the most promising approach in this direction. We expect further studies on JCV-specific 
immunity to explore biomarkers of PML risk, for prognostic estimates and particularly with respect to developing 
vaccination approaches to prevent or treat PML. 
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 Figure legends 
 
Figure 1. Mechanisms used by brain-infiltrating VP1-specific CD4+ T cells to mount efficient immune responses 
against neurotropic JC virus. These strategies include: HLA-cross-restriction, an ability of a T cell clone (TCC) to 
recognize the same JC viral epitope (yellow circle) on different HLA molecules presented by antigen-presenting cells 
(APC) and thereby enhancing avidity as well as ensuring recognition even in the case of limited expression of one of 
the HLA molecules; T cell receptor (TCR) bias, a phenomenon that explains the recognition of the same JC viral 
epitope (e.g. the immunodominant JCV peptide VP134-48) on a specific HLA molecule by different CD4+ T cell 
clonotypes; functional Th1-2 phenotype that is characterized by simultaneous secretion of IFN-γ and IL-4, which lead 
to strong expression of HLA class II in the tissue and intrathecal anti-JCV antibody production. 
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Table 1. Unsettled questions around JCV-specific immunobiology.   
Features of JCV-specific 
immunity 
• Which antigens and epitopes of JCV are preferentially recognized by 
antibodies and T cells in the CNS? 
• How important are peripheral and intrathecal JCV-specific antibodies for 
controlling JCV infection in the CNS?  
• What is the relevance of NK cells and other arms of the innate immunity 
in keeping JCV at bay? 
• Which immune mechanisms of T cells are used to eliminate JCV-infected 
neurons or glial cells? 
Impact of host immune 
system on JCV “life 
cycle” and tropism 
• Does the immune system force mutations of the JCV genome and changes 
of JCV tropism to neurons or glial cells?  
• Are immune cells involved in the process of JCV infection of CNS tissue, 
e.g. as Trojan horse, and when does JCV infection of CNS tissue occur? 
• Does the immune response to JCV in the CNS differ in the context of 
neuronal or glial JCV infection? 
Influence of JCV 
mutations on host immune 
control 
• Do mutations in the coding region of JCV alter JCV-specific immune 
responses? 
• How quickly may adaptive immune responses adjust to novel mutations in 
the coding region of JCV? 
• Which mechanisms do JC viruses use for immune escape? 
Influence of 
immunotherapies on JCV 
immunity 
• Which arms of JCV-specific immunity are critically influenced by 
immunomodulatory and/or immunosuppressive drugs associated with 
increased PML risk? 
JCV-specific vaccination 
strategies  
• Can active and/or passive JCV-specific vaccine strategies protect against 
or clear JCV infection of CNS? 
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